Bumper Offer - Urjas oil Just @ Rs. 1 X
Zipod DT 100 Tablet is a prescription drug, available for use as Tablet. It is primarily used for the treatment of Urinary Tract Infection, Bronchitis. Other than this, Zipod DT 100 Tablet has some other therapeutic uses, which have been discussed ahead.
Medical history of the patient along with age and gender determines the dosage of Zipod DT 100 Tablet. The condition it has been prescribed for, and the route of administration also determine the right dosage. This information has been provided in detail in the dosage section.
Some other side effects of Zipod DT 100 Tablet have been listed ahead. These side effects of Zipod DT 100 Tablet are usually temporary and subside with the completion of treatment. However, if these continue for a longer time, consult your doctor right away.
In addition, Zipod DT 100 Tablet's effect is Mild during pregnancy and Moderate for lactating mothers. In addition, Zipod DT 100 Tablet's effects on the liver, heart and kidney are discussed below in the Zipod DT 100 Tablet related warnings section.
The section on Zipod DT 100 Tablet contraindications lists all such conditions.
Additionally, Zipod DT 100 Tablet may also adversely react with other medicines. A complete list of these interactions is given below.
You should also be aware that Zipod DT 100 Tablet is safe while driving, and is addiction.
Zipod DT 100 Tablet is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| 13 - 18 years (Adolescent) |
|
| Geriatric |
|
| 2 - 12 years (Child) |
|
| Infant (1 month to 2 years) |
|
Based on research, the following side effects have been observed when Zipod DT 100 Tablet is used -
Moderate
Mild
Is the use of Zipod DT 100 Tablet safe for pregnant women?
Zipod rarely shows harmful effects in in pregnant ladies. Even if it does, the effects are mild
Is the use of Zipod DT 100 Tablet safe during breastfeeding?
Zipod can cause moderate side effects on breastfeeding women. If you feel its side effects, then stop taking this drug and consult your doctor. Take this medicine again only if your doctor advises to do so.
What is the effect of Zipod DT 100 Tablet on the Kidneys?
There may be some adverse effects on kidney after taking Zipod. If you observe any such side effects, stop taking this drug. Consume this medicine again only if your doctor advises you to do so.
What is the effect of Zipod DT 100 Tablet on the Liver?
There may be an adverse effect on the liver after taking Zipod. If you observe any side effects on your body then stop taking this drug. Take this medicine again only if your doctor advises you to do so.
What is the effect of Zipod DT 100 Tablet on the Heart?
Zipod may have mild side effects on the heart. Most people will never see any effect on the heart.
Zipod DT 100 Tablet should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Zipod DT 100 Tablet unless your doctor advises you to do so -
Is this Zipod DT 100 Tablet habit forming or addictive?
No, there is no any evidence that Zipod DT 100 Tablet is addictive.
Is it safe to drive or operate heavy machinery when consuming?
Yes, it is safe to do these activities or work after taking Zipod DT 100 Tablet as it does not make you drowsy.
Is it safe?
Yes, Zipod DT 100 Tablet does not show any kind of adverse effect.
Is it able to treat mental disorders?
No, Zipod DT 100 Tablet cannot treat any kind of mental disorder.
Interaction between Food and Zipod DT 100 Tablet
You can take Zipod DT 100 Tablet with food.
Interaction between Alcohol and Zipod DT 100 Tablet
Information about the interaction of Zipod DT 100 Tablet and alcohol is not currently available because this topic has not been researched yet.
This medicine data has been created by -
B.Pharma, Pharmacy
7 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Vantin® (cefpodoxime proxetil )
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-311
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Vantin® (cefpodoxime proxetil )
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-311
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Vantin® (cefpodoxime proxetil )
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-311
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Vantin® (cefpodoxime proxetil )
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-311
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Vantin® (cefpodoxime proxetil )
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-311